A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/29/2011	CA2803504A1 Diabetes therapy
12/29/2011	CA2803496A1 Heterocyclic compounds, their preparation and their therapeutic application
12/29/2011	CA2803459A1 Alkaloid aminoester derivatives and medicinal compositions thereof
12/29/2011	CA2803458A1 Dialysis precursor composition
12/29/2011	CA2803433A1 Alkaloid aminoester derivatives and medicinal composition thereof
12/29/2011	CA2803432A1 Dialysis precursor composition
12/29/2011	CA2803418A1 Dry powder formulation comprising an antimuscarinic drug
12/29/2011	CA2803416A1 Alkaloid aminoester derivatives and medicinal composition thereof
12/29/2011	CA2803339A1 Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
12/29/2011	CA2803264A1 Procedure for obtaining fatty acids of pharmacological and nutritional interest
12/29/2011	CA2803258A1 Pharmaceutical composition comprising midazolam
12/29/2011	CA2803163A1 Sustained-release therapeutic agent for hypertension and renal dysfunction
12/29/2011	CA2803159A1 New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutano
12/29/2011	CA2803156A1 Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
12/29/2011	CA2803093A1 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
12/29/2011	CA2803056A1 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
12/29/2011	CA2803055A1 Heteroaryl compounds and compositions as protein kinase inhibitors
12/29/2011	CA2802952A1 Niacin mimetics, and methods of use thereof
12/29/2011	CA2802945A1 Niacin mimetics, and methods of use thereof
12/29/2011	CA2802937A1 Polymorphs of an active pharmaceutical ingredient
12/29/2011	CA2802895A1 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
12/29/2011	CA2802756A1 Compositions and methods for stabilizing protein-containing formulations
12/29/2011	CA2802644A1 Antitumor agent using compounds having kinase inhibitory effect in combination
12/29/2011	CA2802541A1 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
12/29/2011	CA2802413A1 Use of an estrogen derivative for the manufacture of pharmaceutical compositions useful for the treatment and/or prevention of psychiatric diseases and for the treatment and prevention of said diseases
12/29/2011	CA2802335A1 Controlled release compositions with reduced food effect
12/29/2011	CA2801928A1 Double stranded rna compounds to rhoa and use thereof
12/29/2011	CA2801818A1 Phosphate ester compound of hydroxy acid substituted phenol ester, preparation method and medical use thereof
12/29/2011	CA2801731A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone
12/29/2011	CA2801623A1 Agent for the treatment of skin conditions
12/29/2011	CA2801582A1 Hydroxy acid ester compound of substituted phenol, preparation method and medical use thereof
12/29/2011	CA2801458A1 Amido-tropane derivatives
12/29/2011	CA2801154A1 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
12/29/2011	CA2801098A1 Tolvaptan solid dispersion and its preparation method
12/29/2011	CA2800970A1 Use of 1h-quinazoline-2,4-diones
12/29/2011	CA2800834A1 Pyrazolo [1,5-a] pyrimidines as antiviral agents
12/29/2011	CA2798019A1 Stabilized active compound
12/29/2011	CA2797874A1 Quinolizidine and indolizidine derivatives
12/29/2011	CA2796192A1 Polymorphs of osi-906
12/29/2011	CA2792966A1 Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors
12/29/2011	CA2788398A1 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
12/29/2011	CA2745102A1 Pharmaceutical composition and method of use to improve organ function
12/28/2011	EP2400021A2 ErbB3 based methods and compositions for treating neoplasms
12/28/2011	EP2399988A2 Cell culture system for replication of HCV through the farnesoid X receptor (FXR) activation or inhibition and diagnostic method for HCV infection
12/28/2011	EP2399948A1 Cationic poly(amino acids) and uses thereof
12/28/2011	EP2399930A1 N-terminally monopegylated polypeptides and process for their preparation
12/28/2011	EP2399921A1 Heterocyclic compound and use thereof
12/28/2011	EP2399917A1 Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3h)-one structure and drugs that comprise same
12/28/2011	EP2399914A1 Fused heterocyclic ring compound
12/28/2011	EP2399911A1 Polymorphs of Febuxostat
12/28/2011	EP2399910A1 Novel triazine derivative and pharmaceutical composition containing same
12/28/2011	EP2399909A1 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors
12/28/2011	EP2399908A1 Polymorphic form of 7-ethyl-10[4-(1-piperidino)-1- piperidino]carbonyloxy- camptothecin and its use
12/28/2011	EP2399904A1 Process for the preparation of pleuromutilins
12/28/2011	EP2399903A1 Ccr9 inhibitors and methods of use thereof
12/28/2011	EP2399648A2 Cosmetic composition and use of same
12/28/2011	EP2399611A2 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metasatases in cancer treatment
12/28/2011	EP2399607A1 Transdermal preparation
12/28/2011	EP2399593A1 Semuloparin for use as an antithrombotic treatment in orthopaedic surgery with improved benefit-risk profile
12/28/2011	EP2399592A1 Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
12/28/2011	EP2399591A1 Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
12/28/2011	EP2399590A1 Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
12/28/2011	EP2399589A1 Hydrogel of polysaccharide derivatives
12/28/2011	EP2399588A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
12/28/2011	EP2399587A1 Liposome treatment of viral infections
12/28/2011	EP2399586A1 Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
12/28/2011	EP2399585A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
12/28/2011	EP2399584A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
12/28/2011	EP2399583A1 Use of vaginally-administered insulin sensitizing agents
12/28/2011	EP2399582A1 Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
12/28/2011	EP2399581A1 Drug detoxification protocol using microdosing
12/28/2011	EP2399580A1 Pharmaceutical dosage forms
12/28/2011	EP2399579A1 Pharmaceutical dosage forms
12/28/2011	EP2399578A1 Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
12/28/2011	EP2399577A1 Use of N-containing spirocompounds for the enhancement of cognitive function
12/28/2011	EP2399576A1 Use of antibacterial compounds for the oral cavity hygiene
12/28/2011	EP2399575A2 Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition
12/28/2011	EP2399573A1 Compositions comprising poorly water soluble pharmaceutical agents
12/28/2011	EP2399566A1 Once-a-month method of contraception
12/28/2011	EP2399555A1 Sustainedly drug-releasing hydrogel contact lens, and drug releasing method using sustainedly drug-releasing hydrogel contact lens
12/28/2011	EP2399463A1 Dispersion of phytosterols
12/28/2011	EP2398903A1 Means for inhibiting the expression of ang2
12/28/2011	EP2398902A1 Methods and compositions for diagnosis and treatment of cancer
12/28/2011	EP2398901A1 Jarid1b for target gene of cancer therapy and diagnosis
12/28/2011	EP2398816A1 Nucleic acids specifically binding with human factor vii/viia and uses thereof
12/28/2011	EP2398815A2 Synthesis of ara-2'-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeutics, diagnostics, g- tetrad forming oligonucleotides and aptamers
12/28/2011	EP2398810A1 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
12/28/2011	EP2398809A1 Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
12/28/2011	EP2398807A1 (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
12/28/2011	EP2398806A1 (+)-morphinanium n-oxides and processes for their production
12/28/2011	EP2398805A1 (+)-morphinanium quaternary salts and processes for their production
12/28/2011	EP2398804A2 Acid addition salt of udenafil, preparation method thereof and phamaceutical composition comprising the same
12/28/2011	EP2398803A2 Solid state forms of sitagliptin salts
12/28/2011	EP2398802A1 DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF
12/28/2011	EP2398801A1 3, 3' -spiroindolinone derivatives as anticancer agents
12/28/2011	EP2398800A1 Pyrimidin-4(3h)-one derivatives
12/28/2011	EP2398799A2 Pyridocarbazole type compounds and applications thereof
12/28/2011	EP2398798A1 Triazolopyridine derivatives as p38 map kinase inhibitors
12/28/2011	EP2398797A1 Pyrimido [5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
12/28/2011	EP2398796A1 Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

1 ... 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 ... 7860